Predictive and Prognostic Factors Related to Chemoradioresistance in Neoadjuvant Treatment of Locally Advanced Rectal Cancer at Panama

Daliana Jerez, Carla Luz, Jose Llerena, Rafael Arauz
{"title":"Predictive and Prognostic Factors Related to Chemoradioresistance in Neoadjuvant Treatment of Locally Advanced Rectal Cancer at Panama","authors":"Daliana Jerez, Carla Luz, Jose Llerena, Rafael Arauz","doi":"10.11648/j.crj.20241202.11","DOIUrl":null,"url":null,"abstract":"<i>Background:</i> In Panama, and the rest of Latin America, there are few publications on chemoradioresistance, it leads to poor prognosis and represents the main reason for failure of therapy, ultimately it can lead to tumor recurrence and metastasis. <i>Objective:</i> Identify factors associated with chemoradioresistance in the neoadjuvant treatment of locally advanced rectal cancer at the Instituto Oncológico Nacional de Panamá, period 2016-2020. Methodology: This retrospective study included 71 patients with LARC who received neoadjuvant chemoradiotherapy and surgery. Chemoradioresistant patients were those who did not reach a higher pathological stage of ypT2NO and the results were compared. <i>Results:</i> Of the 71 patients, pathological complete response (pCR) was achieved in 34 patients (48%). 49% of patients met chemoradioresistance criteria. In this group, the median CEA was 136 ng/ml, the median hemoglobin was 12 g/dl, and the median BMI was 26 kg/m2. The median radiation dose was 5000Gy. The time between completion of chemoradiotherapy and surgery was 110 days (16 weeks). Depending on the type of surgery, 65% who underwent low anterior resection were chemoradioresistant. The variables with statistical significance were the CEA value >5 ng/mL (OR=1.81, p=0.026) prior to the start of neoadjuvant treatment, with a lower pCR rate. Likewise, the ECOG scale (OR=2.51, p=0.015) was a risk factor related to chemoradioresistance, the lower the ECOG, the lower the risk of chemoradioresistance. The median overall survival and median recurrence-free survival was not reached in both groups and there was no statistically significant difference. <i>Conclusions:</i> Significant interactions were identified between CEA levels prior to the start of neoadjuvant treatment with the pathological complete response rate and the ECOG score with chemoradioresistance. Therefore, these factors can be used to predict patient outcomes, will help optimize personalized treatment strategies and improve patient outcomes.","PeriodicalId":503171,"journal":{"name":"Cancer Research Journal","volume":"76 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/j.crj.20241202.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In Panama, and the rest of Latin America, there are few publications on chemoradioresistance, it leads to poor prognosis and represents the main reason for failure of therapy, ultimately it can lead to tumor recurrence and metastasis. Objective: Identify factors associated with chemoradioresistance in the neoadjuvant treatment of locally advanced rectal cancer at the Instituto Oncológico Nacional de Panamá, period 2016-2020. Methodology: This retrospective study included 71 patients with LARC who received neoadjuvant chemoradiotherapy and surgery. Chemoradioresistant patients were those who did not reach a higher pathological stage of ypT2NO and the results were compared. Results: Of the 71 patients, pathological complete response (pCR) was achieved in 34 patients (48%). 49% of patients met chemoradioresistance criteria. In this group, the median CEA was 136 ng/ml, the median hemoglobin was 12 g/dl, and the median BMI was 26 kg/m2. The median radiation dose was 5000Gy. The time between completion of chemoradiotherapy and surgery was 110 days (16 weeks). Depending on the type of surgery, 65% who underwent low anterior resection were chemoradioresistant. The variables with statistical significance were the CEA value >5 ng/mL (OR=1.81, p=0.026) prior to the start of neoadjuvant treatment, with a lower pCR rate. Likewise, the ECOG scale (OR=2.51, p=0.015) was a risk factor related to chemoradioresistance, the lower the ECOG, the lower the risk of chemoradioresistance. The median overall survival and median recurrence-free survival was not reached in both groups and there was no statistically significant difference. Conclusions: Significant interactions were identified between CEA levels prior to the start of neoadjuvant treatment with the pathological complete response rate and the ECOG score with chemoradioresistance. Therefore, these factors can be used to predict patient outcomes, will help optimize personalized treatment strategies and improve patient outcomes.
巴拿马新辅助治疗局部晚期直肠癌化疗耐药性的预测和预后因素
背景:在巴拿马和拉丁美洲其他国家,有关化疗耐药性的出版物很少,化疗耐药性导致预后不良,是治疗失败的主要原因,最终可能导致肿瘤复发和转移。研究目的确定 2016-2020 年期间巴拿马国立肿瘤研究所局部晚期直肠癌新辅助治疗中与化疗耐药相关的因素。研究方法:这项回顾性研究纳入了71名接受新辅助化放疗和手术治疗的局部晚期直肠癌患者。化疗耐药患者为未达到ypT2NO较高病理分期的患者,并对结果进行比较。结果在 71 例患者中,34 例患者(48%)获得了病理完全反应(pCR)。49%的患者符合化疗耐药标准。这组患者的 CEA 中位数为 136 ng/ml,血红蛋白中位数为 12 g/dl,体重指数中位数为 26 kg/m2。中位放射剂量为 5000Gy。完成化放疗和手术之间的间隔时间为110天(16周)。根据手术类型,65%接受低位前切除术的患者对化疗耐药。具有统计学意义的变量有:新辅助治疗开始前的CEA值>5 ng/mL(OR=1.81,P=0.026),pCR率较低。同样,ECOG评分(OR=2.51,P=0.015)也是与化疗耐药相关的风险因素,ECOG越低,化疗耐药的风险越低。两组患者的中位总生存期和中位无复发生存期均未达标,差异无统计学意义。结论研究发现,新辅助治疗开始前的CEA水平与病理完全反应率、ECOG评分与化疗耐药之间存在显著的交互作用。因此,这些因素可用于预测患者的预后,有助于优化个性化治疗策略,改善患者预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信